Randomized trial of tacrolimus in combination with sirolimus or mycophenolate mofetil in kidney transplantation: results at 6 months1
The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Abstract
BACKGROUND: This is the first report of a randomized, multicenter, clinical trial comparing the combination of sirolimus or mycophenolate mofetil (MMF) with tacrolimus-based immunosuppression in kidney transplantation. Results at 6 months of follow-up are presented. METHODS: Before transplantation, patients were randomized to receive tacrolimus plus corticosteroids with sirolimus (n=185) or MMF (n=176). The primary endpoint of the study was the incidence of biopsy-confirmed acute rejection. Patient and graft survival, renal function, and composite endpoints also were evaluated. Safety was assessed by monitoring laboratory parameters and adverse events. RESULTS: By 6 months of follow-up, the incidence of biopsy-confirmed acute rejection was similar in both treatment groups (13.0% tacrolimus+sirolimus vs. 11.4% tacrolimus+MMF; P=0.64 log-rank). Patient survival (97.3% tacrolimus+sirolimus vs. 97.7% tacrolimus+MMF) and graft survival (93.0% tacrolimus+sirolimus vs. 95.5% tacrolimus+MMF) were equivalent (P=0.53, overall survival log-rank). There was a significantly higher incidence of study drug discontinuation in patients receiving sirolimus (21.1% vs. 10.8%; P=0.008). Renal function was significantly better in the MMF-treatment group (serum creatinine 1.44+/-0.45 mg/dL vs. 1.77+/-1.42 mg/dL; P=0.018). Hyperlipidemia was significantly more prevalent in the sirolimus-treatment group. Diastolic blood pressure was significantly higher in sirolimus-treated patients. There were significantly more leukopenia and gastrointestinal adverse events in the MMF-treatment group. The incidence of posttransplant diabetes mellitus was 7.6% in the sirolimus group and 7.7% in the MMF group. CONCLUSION: Tacrolimus is equally effective in renal transplantation when combined with sirolimus or MMF. The tacrolimus-MMF combination may be superior in terms of improved renal function and improved cardiovascular risk factors including hyperlipidemia and hypertension.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Banff 97 working classification of renal allograft pathology
Racusen, L. C., Solez, K., Colvin, R. B., Bonsib, S. M., Castro, M. C., Cavallo, T., Croker, B. P., Demetris, A. J., Drachenberg, C. B., Fogo, A. B., et al. (1999) · Kidney International · doi:10.1046/j.1523-1755.1999.00299.x · Cited by 3,033 · cited 1×
“Secondary efficacy endpoints included patient and graft survival, severity of acute rejection determined by histologic grade (10), and the requirement for antilymphocyte antibody therapy.”
BackgroundKahan, B. D. (2000) · The Lancet · doi:10.1016/s0140-6736(00)02480-6 · Cited by 913 · cited 6×
“Additionally, unlike the combination of CsA and sirolimus, the combination of tacrolimus and sirolimus does not cause a substantial increase in sirolimus exposure and there is a decrease in tacrolimus exposure of 25% to 30% when the two drugs are combined (9,15).”
BackgroundResultInfluentialGroth, C. G., Bäckman, L., Morales, J.-M., Calne, R., Kreis, H., Lang, P., Touraine, J.-L., Claesson, K., Campistol, J. M., Durand, D., et al. (1999) · Transplantation · doi:10.1097/00007890-199904150-00017 · Cited by 878
Post-transplant renal function in the first year predicts long-term kidney transplant survival
Hariharan, S., Mcbride, M. A., Cherikh, W. S., Tolleris, C. B., Bresnahan, B. A., & Johnson, C. P. (2002) · Kidney International · doi:10.1046/j.1523-1755.2002.00424.x · Cited by 748 · cited 1×
“In addition, independent analyses have demonstrated that serum-creatinine measurements over the first year after transplantation are excellent surrogate markers of long-term graft survival (17,18).”
BackgroundMacDonald, A. S. (2001) · Transplantation · doi:10.1097/00007890-200101270-00019 · Cited by 621 · cited 6×
“Additionally, unlike the combination of CsA and sirolimus, the combination of tacrolimus and sirolimus does not cause a substantial increase in sirolimus exposure and there is a decrease in tacrolimus exposure of 25% to 30% when the two drugs are combined (9,15).”
BackgroundResultInfluentialJohnson, R. W. G., Kreis, H., Oberbauer, R., Brattstrom, C., Claesson, K., & Eris, J. (2001) · Transplantation · doi:10.1097/00007890-200109150-00007 · Cited by 433
Sirolimus-tacrolimus combination immunosuppression
McAlister, V. C., Gao, Z., Peltekian, K., Domingues, J., Mahalati, K., & MacDonald, A. S. (2000) · The Lancet · doi:10.1016/s0140-6736(99)03882-9 · Cited by 323
Johnson, C., Ahsan, N., Gonwa, T., Halloran, P., Stegall, M., Hardy, M., Metzger, R., Shield, C., Rocher, L., Scandling, J., et al. (2000) · Transplantation · doi:10.1097/00007890-200003150-00028 · Cited by 294
Self-citationLieberthal, W., Fuhro, R., Andry, C. C., Rennke, H., Abernathy, V. E., Koh, J. S., Valeri, R., & Levine, J. S. (2001) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.2001.281.4.f693 · Cited by 270 · cited 9×
“However the incidence of DGF and acute-tubular necrosis was higher in the MMF group, although this difference did not reach significance, P 0.07.”
BackgroundInfluentialGonwa, T. A., Hricik, D. E., Brinker, K., Grinyo, J. M., & Schena, F. P. (2002) · Transplantation · doi:10.1097/00007890-200212150-00013 · Cited by 165
Self-citation
Cited by
Immunosuppressive Drugs for Kidney Transplantation
Halloran, P. F. (2004) · New England Journal of Medicine · doi:10.1056/nejmra033540 · Cited by 1,555
Special Issue: KDIGO Clinical Practice Guideline for the Care of Kidney Transplant Recipients
Eckardt, K.-U., Kasiske, B. L., & Zeier, M. G. (2009) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2009.02834.x · Cited by 1,499
Calcineurin Inhibitor Nephrotoxicity
Naesens, M., Kuypers, D. R. J., & Sarwal, M. (2009) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.04800908 · Cited by 1,489
Sirolimus Is Associated with New-Onset Diabetes in Kidney Transplant Recipients
Johnston, O., Rose, C. L., Webster, A. C., & Gill, J. S. (2008) · Journal of the American Society of Nephrology · doi:10.1681/asn.2007111202 · Cited by 359
Webster, A. C., Lee, V. W. S., Chapman, J. R., & Craig, J. C. (2006) · Transplantation · doi:10.1097/01.tp.0000219703.39149.85 · Cited by 335
Ekberg, H., Bernasconi, C., Tedesco-Silva, H., Vítko, S., Hugo, C., Demirbas, A., Reyes Acevedo, R., Grinyó, J., Frei, U., Vanrenterghem, Y., et al. (2009) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2009.02726.x · Cited by 334
Dean, P. G., Lund, W. J., Larson, T. S., Prieto, M., Nyberg, S. L., Ishitani, M. B., Kremers, W. K., & Stegall, M. D. (2004) · Transplantation · doi:10.1097/01.tp.0000123082.31092.53 · Cited by 332
Post-Transplant Diabetes Mellitus: Causes, Treatment, and Impact on Outcomes
Shivaswamy, V., Boerner, B., & Larsen, J. (2016) · Endocrine Reviews · doi:10.1210/er.2015-1084 · Cited by 328
Larson, T. S., Dean, P. G., Stegall, M. D., Griffin, M. D., Textor, S. C., Schwab, T. R., Gloor, J. M., Cosio, F. G., Lund, W. J., Kremers, W. K., et al. (2006) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2005.01177.x · Cited by 299
Metabolic syndrome and liver transplantation: A review and guide to management
Watt, K. D. S., & Charlton, M. R. (2010) · Journal of Hepatology · doi:10.1016/j.jhep.2010.01.040 · Cited by 245
Mammalian target of rapamycin inhibitor dyslipidemia in kidney transplant recipients
Kasiske, B. L., de Mattos, A., Flechner, S. M., Gallon, L., Meier-Kriesche, H.-U., Weir, M. R., & Wilkinson, A. (2008) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2008.02272.x · Cited by 163
“Flechner 20022 (9) SRL+MMF+Pr 31 64%3 255 225 140 125 61 52 296 228 CsA+MMF+Pr 30 53%3 235 220 137 143 55 52 223 205 Gonwa 20034 (12) SRL+T+Pr 185 61%5,6 2186 – 1116 – 54 – 2486 – MMF+T+Pr 176 37%5 192 – 98 – 52 – 196 – Vitko 20067 (15) SRL (2.”
Hypertension After Kidney Transplant
Mangray, M., & Vella, J. P. (2011) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2010.10.048 · Cited by 165
Claes, K., Meier-Kriesche, H.-U., Schold, J. D., Vanrenterghem, Y., Halloran, P. F., & Ekberg, H. (2012) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfr238 · Cited by 75
“This is consistent with previous studies [26, 40] in which it is demonstrated that the increases in cholesterol and triglycerides are likely due to increases in LDL, very low-density lipoprotein (VLDL) and non-HDL cholesterol.”
ResultVanWagner, L. B., Holl, J. L., Montag, S., Gregory, D., Connolly, S., Kosirog, M., Campbell, P., Pine, S., Daud, A., Finn, D., et al. (2020) · American Journal of Transplantation · doi:10.1111/ajt.15706 · Cited by 55
Metadata
- Authors
- Gonwa, T., Mendez, R., Yang, H. C., Weinstein, S., Jensik, S., & Steinberg, S.
- Venue
- Transplantation
- Published
- 2003-04
- Volume
- 75
- Issue
- 8
- Pages
- 1213-1220
- ISSN
- 0041-1337 (ISSN-L)
- OpenAlex
- W2094676257
- Cited by
- 187
- References
- 13
- FWCI
- 10.38
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.